Clinical Trials Using Mirvetuximab Soravtansine

Clinical trials are research studies that involve people. The clinical trials on this list are studying Mirvetuximab Soravtansine. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-6 of 6
  • A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

    This Phase 3 study is designed to compare the efficacy and safety of mirvetuximab soravtansine vs. investigator's choice chemotherapy in patients with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of FRα. Patients will be, in the opinion of the Investigator, appropriate for single-agent therapy for their next line of therapy. Folate receptor alpha (FRα) positivity will be defined by the Ventana FOLR1 (FOLR1-2.1) CDx assay.
    Location: 15 locations

  • A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

    This study is designed to evaluate the efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with platinum-resistant high-grade serous epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of Folate Receptor-Alpha (FRα). Patients will be, in the opinion of the Investigator, appropriate for single-agent therapy for their next line of therapy. All patients will receive single-agent MIRV at 6 mg / kg adjusted ideal body weight administered on Day 1 of every 3-week cycle.
    Location: 10 locations

  • Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients with FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

    This phase I trial studies the side effects and best dose of mirvetuximab soravtansine and gemcitabine hydrochloride in treating patients with folate receptor (FR) alpha-positive ovarian, primary peritoneal, fallopian tube, endometrial, or triple negative breast cancer that has come back. Mirvetuximab soravtansine is a monoclonal antibody, called mirvetuximab, linked to a chemotherapy drug called DM4. Mirvetuximab attaches to FOLR1 positive cancer cells in a targeted way and delivers DM4 to kill them. Drugs used in the chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving mirvetuximab soravtansine and gemcitabine may work better in treating patients with FRalpha-positive ovarian, primary peritoneal, fallopian tube, endometrial, or triple negative breast cancer.
    Location: 2 locations

  • Mirvetuximab Soravtansine and Pembrolizumab for the Treatment of Microsatellite Stable Advanced or Recurrent Endometrial Cancer

    This phase II trial studies how well mirvetuximab soravtansine and pembrolizumab work in treating patients with microsatellite stable endometrial cancer that has spread to other places in the body (advanced) or has come back (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Mirvetuximab soravtansine is an antibody-drug conjugate, a type of agent attaches a chemotherapy drug to a molecule that binds to a protein on the outside of cancer cells. The protein targeted by mirvetuximab soravtansine is called folate receptor-alpha (FRalpha). FRalpha is expressed on the surface of certain cancers, including endometrial cancer cells. Mirvetuximab soravtansine may to kill cancer cells by delivering chemotherapy drugs to cells that have high levels of FRalpha and may also activate immune cells and improving the response to immunotherapies like pembrolizumab. Giving mirvetuximab soravtansine and pembrolizumab may shrink or prevent the growth of endometrial cancers compared to giving pembrolizumab alone.
    Location: Dana-Farber Cancer Institute, Boston, Massachusetts

  • Mirvetuximab Soravtansine for the Treatment of Folate Receptor-Alpha Positive Persistent or Recurrent Endometrial Cancer

    This phase II trial studies the effect of mirvetuximab soravtansine in treating patients with folate receptor-alpha positive endometrial cancer that remains despite treatment (persistent) or has come back (recurrent). Mirvetuximab soravtansine is a monoclonal antibody, called mirvetuximab, linked to a chemotherapy drug, called soravtansine. Mirvetuximab is a form of targeted therapy because it attaches to specific receptors on the surface of cancer cells, known as folate receptor-alpha receptors, and delivers soravtansine to kill them.
    Location: Yale University, New Haven, Connecticut

  • Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants with Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

    This phase I trial studies the side effects and best dose of mirvetuximab soravtansine and rucaparib camsylate in treating participants with endometrial, ovarian, fallopian tube or primary peritoneal cancer that has come back. Drugs such as mirvetuximab soravtansine are antibodies linked to a toxic substance and may help find certain tumor cells and kill them without harming normal cells. Rucaparib camsylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving mirvetuximab soravtansine and rucaparib camsylate may work better in treating participants with recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio